Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
About HeartMate 3

About HeartMate 3 LVAD with Full MagLev Flow Technology

The HeartMate 3™ LVAD with Full MagLev™ Flow Technology has significantly advanced the field of LVAD therapy, setting the standard with innovation and outstanding clinical outcomes that make a meaningful difference in your patients’ lives.1

This innovation includes Full MagLev Flow Technology, which maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.1

The HeartMate 3 LVAD is used for advanced heart failure patients needing short- or long-term mechanical circulatory support.

Outcomes made possible by Full MagLev Flow Technology

Full MagLev Flow Technology maintains gentle blood handling to minimize complications and hemocompatibility-related adverse events.

  • Fully levitated, self-centering rotor that does not require hydrodynamic or mechanical bearings
  • Large, consistent blood flow pathways to reduce shear stress3
  • Intrinsic pulsatility to reduce stasis and minimize thrombus3,4
Cut across view of the HeartMate 3 Maglev Pump

This device is commercially available for use in select international markets.

References

  1. Mehra M, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device-Final Report. N Engl J Med. 2019;380:1618-1627.
  2. Abbott data on file.
  3. Bourque K, Cotter C, Dague C, et al. Design rationale and preclinical evaluation of the HeartMate 3 Left Ventricular Assist System for hemocompatibility. Am Soc Artificial Int Organs. 2016;62:375- 383.
  4. Bourque K, Dague C, Farrar D, et al. In vivo assessment of a rotary left ventricular assist deviceinduced artificial pulse in the proximal and distal aorta. Artificial Organs. 2006;30:638-642.
Indications, Safety & Warnings

MAT-2105166 v2.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.



Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.



Do you want to continue? 

YesNo